80776-66-5

Basic information

• Product Name: (E)-6-(2-phenylhydrazono)-8,9-dihydro-6H-pyrido-[2,1-b]quinazolin-11(7H)-one
• CAS NO: 80776-66-5
• Molecular Weight: 304.351
• Mol File: 80776-66-5.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: (E)-6-(2-phenylhydrazono)-8,9-dihydro-6H-pyrido-[2,1-b]quinazolin-11(7H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-6-(2-phenylhydrazono)-8,9-dihydro-6H-pyrido-[2,1-b]quinazolin-11(7H)-one(80776-66-5)
• EPA Substance Registry System: (E)-6-(2-phenylhydrazono)-8,9-dihydro-6H-pyrido-[2,1-b]quinazolin-11(7H)-one(80776-66-5)

Safety Data

• Hazardous Substances Data: 80776-66-5(Hazardous Substances Data)

Upstream product

• 100-63-0 phenylhydrazine 
• 71540-66-4 6,6-Dibromo-6,7,8,9-tetrahydro-11H-pyrido<2,1-b>quinazolin-11-one 
• 578-96-1 11H-pyrido[2,1-b]quinazolin-11-one 
• 118-91-2 ortho-chlorobenzoic acid 
• 71540-69-7 6-Bromo-6,7,8,9-tetrahydro-11H-pyrido<2,1-b>quinazolin-11-one 
• 2446-62-0 7,8,9-trihydropyrido[2,1-b]quinazolin-11(6H)-one 
• 62-53-3 aniline 
• 368858-21-3 9,10,11,12-tetrahydro-4H-pyrido[2,1-b]quinazoline-4,9-dione 
• 1365655-59-9 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butyl acetate 
• 1365655-60-2 2-amino-N-(4-hydroxypentyl)benzamide 
• 111-29-5 1 ,5-pentanediol 
• 2508-29-4 5-hydroxypentylamine 
• 68750-23-2 5-acetoxy-1-pentanol 
• 675-20-7 piperidin-2-one 

Downstream Products

• 84-26-4 rutaecarpine 

Relevant articles and documents

Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease

A series of novel rutaecarpine derivatives were synthesized and subjected to pharmacological evaluation as PDE5 inhibitors. The structure–activity relationships were discussed and their binding conformation and simultaneous interaction mode were further clarified by the molecular docking studies. Among the 25 analogues, compound 8i exhibited most potent PDE5 inhibition with IC50 values about 0.086 μM. Moreover, it also produced good effects against scopolamine-induced cognitive impairment in vivo. These results might bring significant instruction for further development of potential PDE5 inhibitors derived from rutaecarpine as a good candidate drug for the treatment of Alzheimer's disease.

New topoisomerases inhibitors: Synthesis of rutaecarpine derivatives and their inhibitory activity against topoisomerases

A series of rutaecarpine derivatives were prepared by employing previously reported methods and their inhibitory activities against topoisomerase I and II were evaluated. Among them, strongly cytotoxic 10-bromorutaecarpine and 3-chlororutaecarpine showed strong inhibitory activities against topo I and II.

Synthesis and vasodilator effects of rutaecarpine analogues which might be involved transient receptor potential vanilloid subfamily, member 1 (TRPV1)

Rutaecarpine is the major alkaloid component of Wu-Chu-Yu, a well known Chinese herbal drug. It has been reported that rutaecarpine causes the vasodilator, hypotensive effects by stimulation of CGRP synthesis and release via activation of TRPV1. In present study, 23 rutaecarpine analogues were designed and synthesized. Then, the vasodilator effects of theses compounds were screened by rat aortic ring experiment. The result showed that the 14-N atom of rutaecarpine might be the key site for the activity. The 5-carbonyl might make lower contribution to the effect. And simple substitute in indole-ring or quinazoline-ring would not enhance the vasodilator effect unless in proper position with proper group. One of these compounds, 10-methylrutaecarpine, exhibited similar effect with rutaecarpine. Further functional experiments showed its vasodilator and hypotensive effect were related to the stimulation of CGRP release via activation of TRPV1. The vasodilator effects of these compounds were evaluated and the structure-activity relationship was elucidated for the first time. The results suggested a new direction of valuable TRPV1 agonist as anti-hypertensive drugs.